Assessing the contribution of interferon antagonism to the virulence of West African Ebola viruses

Nature Communications

Volumn 6, Issue , 2015, Pages

  Dunham, Eric C ^a   Banadyga, Logan ^a   Groseth, Allison ^a   Chiramel, Abhilash I ^a   Best, Sonja M ^a   Ebihara, Hideki ^a   Feldmann, Heinz ^a   Hoenen, Thomas ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; INTERFERON; KARYOPHERIN ALPHA; PROTEIN VP24; PROTEIN VP35; UNCLASSIFIED DRUG; VIRULENCE FACTOR; VIRUS PROTEIN; VIRAL PROTEIN; VP24 PROTEIN, EBOLA VIRUS; VP35 PROTEIN, FILOVIRUS;

DISEASE TRANSMISSION; EPIDEMIOLOGY; IMMUNE RESPONSE; INHIBITION; INHIBITOR; PUBLIC HEALTH; VIRULENCE; VIRUS;

AMINO ACID SEQUENCE; ARTICLE; CONTROLLED STUDY; EBOLA HEMORRHAGIC FEVER; EBOLAVIRUS; EMBRYO; EPIDEMIC; GENETIC DIFFERENCE; GENOME ANALYSIS; GENOTYPE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; INNATE IMMUNITY; MALI; NONHUMAN; POINT MUTATION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PUBLIC HEALTH; SEQUENCE ALIGNMENT; SIERRA LEONE; SIGNAL TRANSDUCTION; SITE DIRECTED MUTAGENESIS; VIRUS GENE; VIRUS GENOME; VIRUS STRAIN; VIRUS TRANSMISSION; VIRUS VIRULENCE; AFRICA; ANTAGONISTS AND INHIBITORS; CHEMISTRY; GENETICS; HEK293 CELL LINE; MOLECULAR CLONING; PATHOGENICITY;

WEST AFRICA;

EBOLA VIRUS;

AFRICA, WESTERN; CLONING, MOLECULAR; EBOLAVIRUS; HEK293 CELLS; HUMANS; INTERFERON-BETA; VIRAL PROTEINS; VIRAL REGULATORY AND ACCESSORY PROTEINS;

EID: 84938914045     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms9000     Document Type: Article

References (48)

1. Feldmann, H. & Geisbert, T. W. Ebola haemorrhagic fever. Lancet 377, 849-862 (2011).
2. Baize, S. et al. Emergence of Zaire Ebola virus disease in Guinea. N. Engl. J. Med. 371, 1418-1425 (2014).
3. Gire, S. K. et al. Genomic surveillance elucidates Ebola virus origin and transmission during the 2014 outbreak. Science 345, 1369-1372 (2014).
4. Hoenen, T. et al. Mutation rate and genotype variation of Ebola virus from Mali case sequences. Science 348, 117-119 (2015).
5. Prins, K. C. et al. Mutations abrogating VP35 interaction with double-stranded RNA render Ebola virus avirulent in guinea pigs. J. Virol. 84, 3004-3015 (2010).
6. Kash, J. C. et al. Global suppression of the host antiviral response by Ebola-and Marburgviruses: Increased antagonism of the type I interferon response is associated with enhanced virulence. J. Virol. 80, 3009-3020 (2006).
7. Basler, C. F. & Amarasinghe, G. K. Evasion of interferon responses by Ebola and Marburg viruses. J. Interferon Cytokine Res. 29, 511-520 (2009).
8. Cardenas, W. B. et al. Ebola virus VP35 protein binds double-stranded RNA and inhibits alpha/beta interferon production induced by RIG-I signalling. J. Virol. 80, 5168-5178 (2006).
9. Hastie, K. M., Bale, S., Kimberlin, C. R. & Saphire, E. O. Hiding the evidence: Two strategies for innate immune evasion by hemorrhagic fever viruses. Curr. Opin. Virol. 2, 151-156 (2012).
10. Basler, C. F. et al. The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3. J. Virol. 77, 7945-7956 (2003).
11. Prins, K. C., Cardenas, W. B. & Basler, C. F. Ebola virus protein VP35 impairs the function of interferon regulatory factor-activating kinases IKKepsilon and TBK-1. J. Virol. 83, 3069-3077 (2009).
12. Muhlberger, E., Weik, M., Volchkov, V. E., Klenk, H. D. & Becker, S. Comparison of the transcription and replication strategies of marburg virus and Ebola virus by using artificial replication systems. J. Virol. 73, 2333-2342 (1999).
13. Watanabe, S., Noda, T., Halfmann, P., Jasenosky, L. & Kawaoka, Y. Ebola virus (EBOV) VP24 inhibits transcription and replication of the EBOV genome. J. Infect. Dis. 196 (Suppl 2), S284-S290 (2007).
14. Hoenen, T., Jung, S., Herwig, A., Groseth, A. & Becker, S. Both matrix proteins of Ebola virus contribute to the regulation of viral genome replication and transcription. Virology 403, 56-66 (2010).
15. Noda, T., Halfmann, P., Sagara, H. & Kawaoka, Y. Regions in Ebola virus VP24 that are important for nucleocapsid formation. J. Infect. Dis. 196 (Suppl 2), S247-S250 (2007).
16. Hoenen, T., Watt, A., Mora, A. & Feldmann, H. Modeling the lifecycle of Ebola virus under biosafety level 2 conditions with virus-like particles containing tetracistronic minigenomes. J. Vis. Exp. 91, 52381 (2014).
17. Watt, A. et al. A novel life cycle modeling system for ebola virus shows a genome length-dependent role of VP24 in virus infectivity. J. Virol. 88, 10511-10524 (2014).
18. Hoenen, T. et al. Infection of naive target cells with virus-like particles: Implications for the function of ebola virus VP24. J. Virol. 80, 7260-7264 (2006).
19. Mateo, M., Reid, S. P., Leung, L. W., Basler, C. F. & Volchkov, V. E. Ebolavirus VP24 binding to karyopherins is required for inhibition of interferon signalling. J. Virol. 84, 1169-1175 (2010).
20. Reid, S. P. et al. Ebola virus VP24 binds karyopherin alpha1 and blocks STAT1 nuclear accumulation. J. Virol. 80, 5156-5167 (2006).
21. Xu, W. et al. Ebola virus VP24 targets a unique NLS binding site on karyopherin alpha 5 to selectively compete with nuclear import of phosphorylated STAT1. Cell Host Microbe 16, 187-200 (2014).
22. Shabman, R. S., Gulcicek, E. E., Stone, K. L. & Basler, C. F. The Ebola virus VP24 protein prevents hnRNP C1/C2 binding to karyopherin alpha1 and partially alters its nuclear import. J. Infect. Dis. 204 (Suppl 3), S904-S910 (2011).
23. Halfmann, P., Neumann, G. & Kawaoka, Y. The Ebolavirus VP24 protein blocks phosphorylation of p38 mitogen-activated protein kinase. J. Infect. Dis. 204 (Suppl 3), S953-S956 (2011).
24. Hoenen, T. et al. Complete genome sequences of three ebola virus isolates from the 2014 outbreak in west Africa. Genome Announc. 2, pii: E01331-e01314 (2014).
25. Hoenen, T., Groseth, A., De Kok-Mercado, F., Kuhn, J. H. & Wahl-Jensen, V. Minigenomes, transcription and replication competent virus-like particles and beyond: Reverse genetics systems for filoviruses and other negative stranded hemorrhagic fever viruses. Antiviral Res. 91, 195-208 (2011).
26. Luthra, P., Jordan, D. S., Leung, D. W., Amarasinghe, G. K. & Basler, C. F. Ebola virus VP35 interaction with dynein light chain 8 regulates viral RNA synthesis. J. Virol. 89, 5148-5153 (2015).
27. Seth, R. B., Sun, L. & Chen, Z. J. Antiviral innate immunity pathways. Cell Res. 16, 141-147 (2006).
28. Kubota, T. et al. Ebolavirus VP35 interacts with the cytoplasmic dynein light chain 8. J. Virol. 83, 6952-6956 (2009).
29. Leung, D. W. et al. Structure of the Ebola VP35 interferon inhibitory domain. Proc. Natl Acad. Sci. USA 106, 411-416 (2009).
30. Reid, S. P., Cardenas, W. B. & Basler, C. F. Homo-oligomerization facilitates the interferon-antagonist activity of the ebolavirus VP35 protein. Virology 341, 179-189 (2005).
31. Luthra, P. et al. Mutual antagonism between the Ebola virus VP35 protein and the RIG-I activator PACT determines infection outcome. Cell Host Microbe 14, 74-84 (2013).
32. Schumann, M., Gantke, T. & Muhlberger, E. Ebola virus VP35 antagonizes PKR activity through its C-terminal interferon inhibitory domain. J. Virol. 83, 8993-8997 (2009).
33. Prins, K. C. et al. Basic residues within the ebolavirus VP35 protein are required for its viral polymerase cofactor function. J. Virol. 84, 10581-10591 (2010).
34. Lubaki, N. M. et al. The lack of maturation of Ebola virus-infected dendritic cells results from the cooperative effect of at least two viral domains. J. Virol. 87, 7471-7485 (2013).
35. Edwards, M. R. et al. The Marburg virus VP24 protein interacts with Keap1 to activate the cytoprotective antioxidant response pathway. Cell Rep. 6, 1017-1025 (2014).
36. Zhang, A. P. et al. The ebolavirus VP24 interferon antagonist: Know your enemy. Virulence 3, 440-445 (2012).
37. Zhang, A. P. et al. The ebola virus interferon antagonist VP24 directly binds STAT1 and has a novel, pyramidal fold. PLoS Pathog. 8, e1002550 (2012).
38. Groseth, A. et al. The Ebola virus glycoprotein contributes to but is not sufficient for virulence in vivo. PLoS Pathog. 8, e1002847 (2012).
39. Team, W. H. O. E. R.. Ebola virus disease in West Africa-the first 9 months of the epidemic and forward projections. N. Engl. J. Med. 371, 1481-1495 (2014).
40. Longdon, B., Brockhurst, M. A., Russell, C. A., Welch, J. J. & Jiggins, F. M. The evolution and genetics of virus host shifts. PLoS Pathog. 10, e1004395 (2014).
41. Kerr, P. J. Myxomatosis in Australia and Europe: A model for emerging infectious diseases. Antiviral Res. 93, 387-415 (2012).
42. Taubenberger, J. K. & Morens, D. M. 1918 Influenza: The mother of all pandemics. Emerg. Infect. Dis. 12, 15-22 (2006).
43. Tong, Y. G. et al. Genetic diversity and evolutionary dynamics of Ebola virus in Sierra Leone. Nature doi:10.1038/nature14490 (2015).
44. Niwa, H., Yamamura, K. & Miyazaki, J. Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 108, 193-199 (1991).
45. Lennartz, F., Hoenen, T., Lehmann, M., Groseth, A. & Garten, W. The role of oligomerization for the biological functions of the arenavirus nucleoprotein. Arch. Virol. 158, 1895-1905 (2013).
46. Rothenfusser, S. et al. The RNA helicase Lgp2 inhibits TLR-independent sensing of viral replication by retinoic acid-inducible gene-I. J. Immunol. 175, 5260-5268 (2005).
47. Best, S. M. et al. Inhibition of interferon-stimulated JAK-STAT signalling by a tick-borne flavivirus and identification of NS5 as an interferon antagonist. J Virol. 79, 12828-12839 (2005).
48. Leung, D. W. et al. Structural basis for dsRNA recognition and interferon antagonism by Ebola VP35. Nat. Struct. Mol. Biol. 17, 165-172 (2010).